Tempus Announces Publication Of Its Study, "Actionable Structural Variant Detection Via RNA-NGS And DNA-NGS In Patients With Advanced Non-small Cell Lung Cancer," In Jama Network Open
Tempus Announces Publication Of Its Study, "Actionable Structural Variant Detection Via RNA-NGS And DNA-NGS In Patients With Advanced Non-small Cell Lung Cancer," In Jama Network Open
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, "Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer," in JAMA Network Open.
Tempus AI, Inc.（納斯達克股票代碼：TEM）是一家領先採用人工智能推動精準醫學和患者護理的科技公司，今天宣佈其在JAMA Network Open上發表了題爲"通過RNA-NGS和DNA-NGS在患有晚期非小細胞肺癌患者中檢測可操作結構變體"的研究。
Tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (NSCLC) and found that concurrent RNA- and DNA-based next-generation sequencing (NGS) led to the detection of more actionable structural variants compared to DNA sequencing alone. Specifically, 8.8% of patients had at least one actionable variant – ALK, RET, ROS1, or NTRK1/2/3 fusions, or MET exon 14 skipping alterations – identified by one or both assays. Overall, the concurrent use of RNA and DNA sequencing resulted in a 15.3% increase in identifying patients with actionable variants and more than doubled the detection of emerging, rare structural variants compared to DNA sequencing alone. These findings suggest that concurrent RNA and DNA testing should be more widely implemented in clinical settings to maximize the detection of structural variants.
Tempus最近進行了一項回顧性研究，涉及超過5,500名患有晚期非小細胞肺癌（NSCLC）的患者，發現與僅進行DNA測序相比，同時進行RNA和DNA基於下一代測序（NGS）可以更好地檢測可操作結構變體。具體來說，8.8%的患者至少有一種可操作變體——被一個或兩個測定法鑑定的ALk、REt、ROS1或NTRK1/2/3融合體，或MEt外顯子14缺失改變。總體而言，同時使用RNA和DNA測序導致了在識別具有可操作變體的患者方面增加了15.3%，並且與僅進行DNA測序相比，檢測到新興、罕見結構變體的數量翻了一番以上。這些發現表明，應更廣泛地在臨床設置中實施同時進行RNA和DNA測試，以最大程度地檢測出結構變體。
